knowledge -WSS

knowledge

author：fashion 2025-10-01 00:06:40 - browse：23654

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

WSS

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Overprescribed: High cost isn't America's only drug problem

Multiple sclerosis has subtypes with different best treatments: study

Is there really a nursing shortage in the U.S.?

Readout LOUD podcast: Live from the 2023 STAT Summit

Covid silver lining: Unprecedented look at human immune system

Wikipedia

knowledge

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Live from the 2023 STAT Summit

Psychedelics group wrestles with new pharma identity

STAT Readout: Friday, Oct. 20 biotech updates

Novavax promises a turnaround & Lilly roils the obesity market

Multiple sclerosis has subtypes with different best treatments: study

Supreme Court strikes down use of affirmative action

Oral obesity drug from Viking Therapeutics hits key early target

Supreme Court strikes down use of affirmative action

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Wikipedia

Study on Amgen’s bispecific immunotherapy produces positive data

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

UnitedHealth, Optum discontinue NaviHealth name

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Bird flu reported in person exposed to presumably infected cattle

Wikipedia

entertainment

focus

hotspot